Cytonics’ First-In-Class Treatment for Osteoarthritis is Poised to Disrupt the Regenerative Medicine Industry

June 27, 2020

Early-stage biotech investing is not for everyone. The risk is high. The reward is higher. Seasoned investors know the game, but with the abundance of opportunities to invest in early-stage biotech R&D, we believe that specific criteria must be met to warrant serious consideration:

  • A strong, deep management team and advisory board filled with key opinion leaders,
  • a track record of accomplishing R&D and capital raising milestones, and
  • a technology that can disrupt a huge market segment and that is protected by an airtight patent portfolio

Cytonics was founded by Gaetano Scuderi, a world-renowned orthopedic surgeon and research scientist. Cytonics’ core technology was discovered while he was teaching at Stanford: Alpha-2-Macroglobulin (A2M), a naturally occurring blood protein, as a therapy to prevent cartilage damage in osteoarthritis (OA). Dr. Scuderi realized the potential of A2M and founded Cytonics on the principle that our R&D would address this debilitating disease (OA) and bring much needed relief to an expanding population of suffering patients.

The company’s evolution from a pure medical device company to biopharmaceutical research center has a rich history that includes:

  • The discovery of a novel biomarker for osteoarthritis and commercialization of a diagnostic assay (FACT™)
  • The commercialization of an A2M-based autologous therapy (APIC™) to treat arthritic joints
  • The genetic engineering of a recombinant variant of A2M (“CYT-108”) that has the potential to disrupt the entire space upon FDA approval

The company is led by seasoned management from Big Pharma and academia, advised by many PhD and MDs with FDA regulatory experience, has raised over $20M in funding from private capital, and has a track record of taking early-stage biotech products to market. Protected by 8 international patents (with 9 more pending). Cytonics’ mission is to advance CYT-108 into clinical trials and sell the drug asset to Big Pharma in Phase 2.

Download the Investor Brief
see slides 16 and 17 for preclinical study results